Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.

被引：2

作者：

Mobasher, Mehrdad

Huang, Jane

Elstrom, Rebecca L.

Elhamy, Mostafa

Bernaards, Coen

Hallek, Michael J.

Hillmen, Peter

Kater, Arnon Philip

Kipps, Thomas J.

Seymour, John Francis

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Univ Cologne, D-50931 Cologne, Germany

[3] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England

[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[5] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.tps7120

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7120

引用

页数：1

共 50 条

[31] Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study
Stilgenbauer, Stephan
Eichhorst, Barbara F.
Schetelig, Johannes
Coutre, Steven
Seymour, John F.
Munir, Talha
Puvvada, Soham D.
Wendtner, Clemens-Martin
Roberts, Andrew W.
Jurczak, Wojciech
Mulligan, Stephen
Boettcher, Sebastian
Mobasher, Mehrdad
Zhu, Ming
Chyla, Brenda
Verdugo, Maria
Enschede, Sari Heitner
Cerri, Elisa
Humerickhouse, Rod A.
Gordon, Gary
Hallek, Michael
Wierda, William
BLOOD, 2015, 126 (23)
[32] Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)
Chari, Ajai
Goldschmidt, Hartmut
Yang, Shiyi
Kosh, Michele
Delioukina, Maria
Qi, Ming
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E144 - E144
[33] The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
Ramchandren, Radhakrishnan
Johnson, Peter
Ghosh, Nilanjan
Ruan, Jia
Ardeshna, Kirit M.
Johnson, Roderick
Verhoef, Gregor
Cunningham, David
de Vos, Sven
Kassam, Shireen
Fayad, Luis
Radford, John
Bailly, Sarah
Offner, Fritz
Morgan, David
Munoz, Javier
Ping, Jerry
Szafer-Glusman, Edith
Eckert, Karl
Neuenburg, Jutta K.
Goy, Andre
ECLINICALMEDICINE, 2023, 56
[34] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis
Meletios A. Dimopoulos
Darrell J. White
Lotfi Benboubker
Gordon Cook
Merav Leiba
P. Joy Ho
Kihyun Kim
Naoki Takezako
Philippe Moreau
Jonathan L. Kaufman
Maria Krevvata
Christopher Chiu
Xiang Qin
Linda Okonkwo
Sonali Trivedi
Jon Ukropec
Ming Qi
Jesus San-Miguel
Leukemia, 2020, 34 : 1875 - 1884
[35] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Bahlis, Nizar J.
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Ukropec, Jon
Qi, Ming
San-Miguel, Jesus
LEUKEMIA, 2020, 34 (07) : 1875 - 1884
[36] A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.
Richardson, Paul G.
Attal, Michel
Miguel, Jesus San
Campana, Frank
Le-Guennec, Solenn
Hui, Ai-Min
Risse, Marie-Laure
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37] B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase trial.
Nowakowski, Grzegorz S.
Belada, David
Molina, Lysianne
Kopeckova, Katerina
Laribi, Kamel
del Campo Garcia, Raquel
Coiffier, Bertrand
Jurczak, Wojciech
Rummel, Mathias J.
Hess, Georg
Rosenwald, Andreas
Winderlich, Mark
Korolkiewicz, Roman
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Rugo, Hope S.
Umanzor, Gerardo A.
Barrios, Francisco J.
Vasallo, Rosa H.
Chivalan, Marco A.
Bejarano, Suyapa
Ramirez, Julio R.
Fein, Luis
Kowalyszyn, Ruben D.
Kramer, E. Douglas
Wang, Hui
Kwan, Min-Fun R.
Cutler, David L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 65 - +
[39] A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)
Weisel, Katja
Hungria, Vania T. M.
Radinoff, Atanas
Delimpasi, Sosana
Gabor, Mikala
Masszi, Tamas
Li, Jian
Capra, Marcelo
Matsumoto, Morio
Sule, Neal
Li, Mary
McKeown, Astrid
He, Wei
Bright, Shelley
Currie, Brooke
Boyle, Julia
Opalinska, Joanna
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S505
[40] Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy
Lavie, David
Ozcan, Muhit
Chaudhry, Arvind
Zhou, Xuan
Paydar, Ima
Farooqui, Mohammed Z. H.
Ghia, Paolo
BLOOD, 2023, 142

← 1 2 3 4 5 →